[Immunological and epidemiological effectiveness of the HEVAC B vaccine against hepatitis B in a group at enhanced risk of infection].

Abstract

The immunological and epidemiological effectiveness of HEVAC B vaccine against hepatitis B (Pasteur Institute, France) was studied in 215 medical workers of Moscow who had contacts with the blood or preparations thereof. A control group consisted of 155 medical workers. The groups were formed randomly but both included the subjects without HBsAg and anti-HBs. The HEVAC B vaccine was found to be characterized by high immunologic efficacy. Administration of the vaccine induced seroconversion after the 1st, 2nd, and 3rd vaccinations in 36.3%, 77.2%, and 93.9% vaccinees, respectively. In the course of immunization, a marked rise of specific antibody levels was observed. Among the vaccinees no cases of hepatitis B with jaundice were recorded, while in the control group there were 2 cases (1.3%). The vaccine has a low reactogenicity and is safe for use.

• Authors: P A Khukhlovich, S O Viazov, I V Shakhgil'dian, V A Anan'ev, D M Braginskiĭ
• Journal: Voprosy virusologii (Vopr Virusol) 1985 May-Jun Vol. 30 Issue 3 Pg. 330-3 ISSN: 0507-4088 [Print] Russia (Federation)
• Vernacular Title: Izuchenie immunologicheskoĭ i épidemiologicheskoĭ éffektivnosti vaktsiny HEVAC B protiv gepatita B v gruppe povyshennogo riska zarazheniia.
• PMID: 4049844 (Publication Type: Comparative Study, English Abstract, Journal Article)

Chemical References

• Hepatitis B Antibodies
• Viral Hepatitis Vaccines

Topics

• Adolescent
• Adult
• Drug Evaluation
• Female
• Hepatitis B (prevention & control)
• Hepatitis B Antibodies (analysis)
• Humans
• Male
• Medical Staff, Hospital
• Middle Aged
• Moscow
• Risk
• Time Factors
• Viral Hepatitis Vaccines (administration & dosage, adverse effects, immunology)